The clinical benefit of EGFR-TKIs has been demonstrated in NSCLC patients with activating EGFR mutations [8]–[10], but most tumors develop acquired resistance via several different mechanisms, including the secondary T790M mutation that occurs in around 50% of patients with EGFR-TKI resistance [11]–[15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.